会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • GUIDED ORTHODONTIC BRACKET APPLICATION
    • 引导正交支架应用
    • WO2016210402A1
    • 2016-12-29
    • PCT/US2016/039516
    • 2016-06-27
    • UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    • GRAVENSTEIN, NikolausDOLCE, CalogeroLAMPOTANG, SamsunLIZDAS, David, Erik
    • A61C7/14A61C19/04A61C7/00G06F19/00
    • A61C7/002A61C7/146A61C7/28G06F19/00G16H20/40
    • A computer-implemented method and system for guiding the placement of orthodontic brackets are provided. The system can include an at least one indexing tool designed to conform to at least a portion of a patient's teeth or alveolar process. The system can receive signals from a sensor at the indexing tool as well as signals from a sensor at a bracket positioning tool in order to track spatial location -and/or orientation of one or more brackets relative to the surface of the patient's actual or modeled teeth. A method for guiding the placement of orthodontic brackets involves detecting the location and/or orientation of a bracket with respect to at least one tooth of a patient and notifying the orthodontist that the actual bracket position and/or orientation meets specified criteria with respect to planned placement coordinates for the bracket. The method can further include collecting the planned placement coordinates for each bracket tooth combo during a planning phase.
    • 提供了一种用于指导正畸托架放置的计算机实现的方法和系统。 该系统可以包括设计成符合患者牙齿或肺泡过程的至少一部分的至少一个分度工具。 该系统可以在分度工具处接收来自传感器的信号以及来自支架定位工具处的传感器的信号,以便跟踪一个或多个支架相对于患者的实际或建模表面的空间位置和/或取向 牙齿。 用于引导正畸托架放置的方法包括检测支架相对于患者的至少一个牙齿的位置和/或方位,并通知正畸医生实际支架位置和/或方位符合规划的指定标准 支架的放置坐标。 该方法还可以包括在规划阶段收集每个支架齿组合的计划放置坐标。
    • 3. 发明申请
    • METHODS FOR REDUCING ANESTHETIC-INDUCIBLE EPILEPTOGENIC AND NEUROTOXIC EFFECTS
    • 降低麻醉诱导性肾上腺皮质激素和神经毒性作用的方法
    • WO2011146806A1
    • 2011-11-24
    • PCT/US2011/037289
    • 2011-05-20
    • UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.MARTYNYUK, Anatoly, EugenySEUBERT, Christoph, NikolausGRAVENSTEIN, Nikolaus
    • MARTYNYUK, Anatoly, EugenySEUBERT, Christoph, NikolausGRAVENSTEIN, Nikolaus
    • A01N45/00A61K31/56
    • A61K31/585A61K31/08A61K38/11A61K45/06A61K2300/00
    • The disclosure encompasses methods of reducing a neural activity in an animal or human subject. The neural activity may be a seizure that may be, but is not necessarily, an inducible side-effect of an anesthetic in an animal or human subject. The methods include administering to an animal or human subject an anesthetic together with a therapeutic agent selected from an inhibitor of the Na + -K + -2Cl - symport ion co-transporter 1 (NKCC1)agent, a mineralcorticoid receptor (MR) antagonist, or an agonist of an oxytocin receptor or a derivative thereof. The therapeutic agent can be be administered before or with an anesthetic, thereby reducing the likelihood of the onset of a non-anesthesizing effect of the anesthetic or the severity thereof. A suitable mineralcorticoid receptor (MR) antagonist can be 17-spironolactone, and the oxytocin receptor agonist can be, but not limited to, oxytocin, carbetocin, and the like. The neural activity reduced by the methods of the disclosure can include the onset or level of a seizure, a neurotoxicity, a behavioral effect, a cognitive effect.
    • 本公开内容包括减少动物或人类受试者的神经活性的方法。 神经活动可以是可能但并不一定是麻醉剂在动物或人类受试者中的诱导性副作用的发作。 所述方法包括向动物或人类受试者施用麻醉剂,其与选自Na + -K + -2Cl-对称离子共转运蛋白1(NKCC1)抑制剂,盐皮质激素受体(MR)拮抗剂或 催产素受体或其衍生物的激动剂。 治疗剂可以在麻醉之前或与麻醉剂一起施用,从而降低麻醉剂非麻醉作用发生的可能性或其严重性。 合适的皮质激素受体(MR)拮抗剂可以是17-安体舒通内酯,催产素受体激动剂可以是但不限于催产素,卡贝缩酮等。 通过本公开的方法减少的神经活动可以包括发作的发作或水平,神经毒性,行为效应,认知效应。